Peptides, the body project and the problem of oversight

BEAUTY & WELLBEING · HEALTH

A new ideal of the male body is being pursued with substances that regulators have not validated. Injectable peptides, sold as a shortcut to firmer skin, faster recovery and more muscle, have found an audience among young men, and even teenagers, willing to set aside safety warnings in exchange for visible results.

The trade lives largely online, in a grey market of vials labelled “for research use only”, where oversight is thin and provenance uncertain. The appeal of a body sculpted quickly has so far proved stronger than caution.

The body as a project

The pursuit of physical optimisation is not new. What has changed is who is doing it. Compounds that were once the territory of experienced bodybuilders, or of patients under medical care, are now discussed on forums and social platforms where the promise of a visible result outweighs concern about long-term effects that nobody has measured.

Peptides with names such as BPC-157, TB-500, GHK-Cu, Ipamorelin and CJC-1295 now circulate in wellness podcasts, biohacking communities and longevity clinics, usually accompanied by claims about muscle repair, metabolism, skin quality, cognition and healthy ageing. Online communities have even given their combinations nicknames, the “Wolverine stack” among them, for blends associated with healing and recovery.

What the science supports, and what it does not

The curiosity has some legitimate roots. GHK-Cu, a copper peptide, has been studied for skin regeneration and wound healing, and it appears in topical cosmetics. Most of the evidence for BPC-157, the best known of the injectables, comes from animal studies; robust human trials are close to non-existent. None of the peptides in the popular stacks is an approved medicine in the United States or the European Union for the uses being promoted, and none has validated dosing.

The risks of the grey market are concrete. Independent testing of vials sold online has reported bacterial contamination, residual solvents and heavy metals, and doses that do not match the label. Injecting an unregulated product adds the familiar dangers of infection and impurity to the unknown effects of the compound itself. In 2025, more than forty US state attorneys general wrote to the FDA about contamination and safety concerns.

Where regulation stands

In the United States, the regulatory picture has moved quickly in 2026, and it is easy to misread. In February, the Department of Health and Human Services announced that most of the peptides on the FDA’s restricted compounding list would be reconsidered. In July, the FDA’s Pharmacy Compounding Advisory Committee voted to recommend six peptides, including BPC-157 and TB-500, for the list of substances that pharmacies may compound on prescription, although the agency’s own scientists had recommended against them for lack of human clinical data.

That vote is advisory, not binding. As of October 2026 the FDA has not added these peptides to the list, and any change would require formal rulemaking that could take a year or more. Compounding eligibility would not, in any case, amount to approval: it would mean a pharmacist could prepare the substance for an individual prescription, not that its safety or efficacy had been established.

Trust as the only currency

Within the industry, the more responsible operators make the same argument. Michael Mirmanesh, a plastic surgeon working in regenerative medicine, describes the demand as part of a move towards proactive longevity, with patients seeking care beyond conventional models. Koehl Robinson, founder of the longevity telehealth platform Celia Rx, notes that interest has widened from metabolic peptides to a broader category built around cellular health and healthy ageing, with women in particular asking about hormonal and reproductive health. Both depend, commercially, on the category being trusted.

That trust is eroded by questionable sourcing, missing traceability, unstandardised preparations and the absence of clinical supervision. The useful questions are not paranoid ones. Where does the product come from? Is it traceable? Which doctor is responsible? What does the evidence actually show, as opposed to the marketing? And who answers when something goes wrong?

Anyone considering a peptide should speak to a qualified physician first, and treat any product sold without a prescription, or labelled for research only, as unsuitable for human use.

For a generation raised on the logic of constant optimisation, the question of how far control over one’s own body justifies risk is still being answered, one injection at a time. The better answer may begin with a slower question: who, exactly, is responsible for what goes in the syringe.

GABRIEL SILVEIRADO, FOR WAYFARER.